Skip to Main content

ABPI News - Archive

ABPI News archive

2023

14 December 2023 - 2024 Voluntary Scheme agreement published
13 December 2023 - ABPI and PMCPA consult on changes to the pharmaceutical industry code of practice
13 December 2023 - ABPI welcomes ambitious NHS vaccination strategy
07 December 2023 - Latest economic data underlines risk of disincentivising UK life sciences growth
05 December 2023 - Government sends mixed message to global life science investors
30 November 2023 - ABPI response to UK Biobank whole genome sequencing dataset
24 November 2023 - Break down barriers to partnerships to change the lives of millions, say NHS Confederation and the ABPI
22 November 2023 - ABPI comment on Government's full response to the O'Shaughnessy Review
22 November 2023 - ABPI response to Autumn Statement 2023
20 November 2023 - Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
17 November 2023 - UK industry clinical trial performance shows signs of improvement, says ABPI report
14 November 2023 - The UK must harness the power of advanced manufacturing
02 November 2023 - UK antibiotic subscription model key to supporting antibiotic investment
12 October 2023 - UK faces £50bn economic hit due to spiralling medicines levy
09 October 2023 - Life sciences leaders unite to condemn radical plans to rewrite medicines scheme
29 September 2023 - At risk: NHS access to new medicines, investment and research
22 September 2023 - ABPI welcomes rare diseases research landscape report
07 September 2023 - ABPI response: UK joins Horizon Europe
29 August 2023 - Pharmaceutical companies maintain reputation post-pandemic, new research finds
25 August 2023 - ABPI response to research on the Innovative Medicines Fund
16 August 2023 - ABPI response to £210 million DHSC antimicrobial awareness funding
07 August 2023 - ABPI response to UKHSA Vaccine Development and Evaluation Centre (VDEC) announcement
27 July 2023 - ABPI response to health and social care committee report on vaccination
19 July 2023 - New government consultation on medicine clawbacks will harm investment, says ABPI
13 July 2023 - UK life science inward investment in freefall
10 July 2023 - ABPI response to BGMA Judicial Review dismissal
30 June 2023 - ABPI response to NHS Long Term Workforce Plan
30 June 2023 - Boost for transparency as highest ever rate of healthcare professionals named on Disclosure UK
26 June 2023 - New report from The King’s Fund shows the UK underperforming on treatable health conditions, says the ABPI
15 June 2023 - ABPI comment on BGMA proposals for a new Voluntary Scheme
13 June 2023 - Boost UK manufacturing to attract £15 billion new investment, says medicines manufacturing alliance
08 June 2023 - UK life sciences in search for AI, digital and data talent
08 June 2023 - CBI extraordinary general meeting outcome
26 May 2023 - UK’s grand ambition for life sciences hinges on delivery
24 May 2023 - Susan Rienow becomes President of the ABPI
22 May 2023 - ABPI response to DHSC antimicrobial resistance research funding
18 May 2023 - Jessamy Baird of Sanofi named as new ABPI Vice-President Elect
15 May 2023 - ABPI response to launch of UK and Switzerland free trade agreement negotiations
04 May 2023 - Negotiations begin for a new medicine pricing scheme
28 April 2023 - EFPIA WAIT indicator survey 2022 launches
27 April 2023 - ABPI Conference 2023: Chief Executive speech
26 April 2023 - ABPI response to charity joint statement on the Voluntary Scheme
22 April 2023 - ABPI statement on CBI
21 April 2023 - ABPI statement on BGMA legal action over Voluntary Scheme negotiation representation
04 April 2023 - ABPI response to the Hewitt Review recommendations
03 April 2023 - Five new patient organisation leaders to join ABPI Patient Advisory Council
28 March 2023 - MMIP chair responds to Life Sciences Innovative Manufacturing Fund grants announcement
23 March 2023 - ABPI welcome the appointment of Sir Hugh Taylor to key role in Voluntary Scheme negotiations
21 March 2023 - ABPI response to MHRA clinical trials framework
16 March 2023 - Novo Nordisk is suspended from ABPI membership
15 March 2023 - ABPI response to the Budget
15 March 2023 - ABPI welcomes new NHS research guidance
10 March 2023 - ABPI refreshes its commitment to improve public involvement in research
08 March 2023 - Susan Rienow of Pfizer confirmed as next President of the ABPI
06 March 2023 - ABPI response to Science and Technology Framework publication
02 March 2023 - ABPI response to government Statutory Scheme rise
01 March 2023 - ABPI sets out new proposals to support the NHS and economic growth
28 February 2023 - ABPI response to England's 2023 Rare Disease Action Plan
28 February 2023 - Pharmaceutical industry a key player in Scotland’s life sciences sector
27 February 2023 - ABPI respond to the new Northern Ireland Brexit deal
20 February 2023 - ABPI response to Lord O'Shaughnessy Review
04 February 2023 - Pinder Sahota to step down as ABPI President
02 February 2023 - Pharma industry urges halt to further rises in record revenue clawbacks
01 February 2023 - ABPI response to new MHRA fees announced for 1 April 2023
24 January 2023 - Medicines manufacturing has the potential to drive UK growth over the next 10 years
24 January 2023 - ABPI response to MHRA European Commission Decision Reliance Procedure (ECDRP) announcement
17 January 2023 - ABPI response to Applied Health Economics and Health Policy paper: “Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?”
17 January 2023 - Better health system partnerships can improve equality of access to innovative medicines
16 January 2023 - Leading global pharma firms exit UK drug pricing agreement
13 January 2023 - Moderna joins the Association of the British Pharmaceutical Industry
03 January 2023 - ABPI statement on the death of Professor Sir Michael Rawlins GBE Kt

2022

13 January 2022 UK pharmaceutical industry welcomes India trade talks
13 January 2022 Gilead Sciences joins the ABPI
19 January 2022 Pharmaceutical industry sets out manifesto for the next Northern Ireland Assembly
19 January 2022 ABPI response to NICE review of how medicines and health technologies are evaluated
27 January 2022 Report: Pharmaceutical industry needs more digital talent
02 February 2022 Industry response to Levelling Up White Paper
04 February 2022 Pharmaceutical industry response to national war on cancer
09 February 2022 Pharmaceutical industry working to build public trust with new data principles
09 February 2022 Infection Management Coalition launches
15 February 2022 CSL Behring joins the ABPI
23 February 2022 ABPI appoints new Director of PMCPA
24 February 2022 Speech: Life sciences companies can be part of the cure for climate change
25 February 2022 Global research allies critical to UK’s ‘science superpower’ ambitions
25 February 2022 Pfizer’s Brian Henry appointed head of UK medicines manufacturing partnership
28 February 2022 ABPI welcomes Health and Care Bill amendments on research
28 February 2022 ABPI response to England Rare Diseases Action Plan
02 March 2022 ABPI response to Life Sciences Innovative Manufacturing Fund announcement
02 March 2022 New funding to support data access for health research - ABPI response
02 March 2022 ABPI response to new funding for UK medicines manufacturing
08 March 2022 Statement on Global Pandemic Preparedness Summit & CEPI Replenishment
11 March 2022 Health and social care leaders unite to improve public involvement in research
17 March 2022 ABPI response to TRIPS waiver proposals
18 March 2022 ABPI welcomes new UK ambitions to accelerate genomic research
23 March 2022 ABPI welcomes Northern Ireland Cancer Strategy
23 March 2022 Spring Statement 2022
23 March 2022 ABPI response to Northern Ireland's Rare Diseases Action Plan
05 April 2022 ABPI response to Commons cancer services report
06 April 2022 New EFPIA WAIT indicator survey launches
07 April 2022 New EFPIA WAIT Indicators launched
07 April 2022 ABPI response to the Goldacre Review
12 April 2022 ABPI response to guidance on the value of new antibiotics
29 April 2022 Novo Nordisk’s Pinder Sahota appointed President of the ABPI
29 April 2022 ABPI welcomes appointment of Madelaine McTernan as Head of HRT Taskforce
05 May 2022 ABPI response to meeting between industry and Government on HRT supply
12 May 2022 ABPI response to 'Healthy Mum, Healthy Baby, Healthy Future' report
13 May 2022 Eligible NHS patients missing out on new medicines that could extend lives and add £billions to the UK economy
24 May 2022 Northern Ireland life sciences sector continues strong economic output
07 June 2022 ABPI response to Innovative Medicines Fund announcement
13 June 2022 ABPI response to Data Strategy publication
15 June 2022 New approach to antibiotics good news for patients
22 June 2022 ABPI welcomes Moderna investment
30 June 2022 Act now to bring £68bn economic boost to the UK through new research investment
30 June 2022 ABPI response to Clinical Research Implementation Plan publication
30 June 2022 Latest Disclosure UK data: Highest ever rate of health professionals agreeing to be named
12 July 2022 Pharmaceutical companies commit to new principles on using NHS data for research
12 July 2022 ABPI response to appointment of new Patient Safety Commissioner
14 July 2022 ABPI awarded PIF TICK trusted healthcare information creator status
20 July 2022 ABPI welcomes first women's health strategy for England
21 July 2022 ABPI response to Life Sciences Competitiveness Indicators
08 August 2022 ABPI statement on biomarker testing
11 August 2022 Open letter to Secretary of State for International Trade on UK-India negotiations
07 September 2022 ABPI joins the Sustainable Medicines Partnership
08 September 2022 ABPI statement on the death of Her Majesty Queen Elizabeth II
15 September 2022 Susan Rienow of Pfizer named Vice-President of the ABPI
22 September 2022 ABPI statement on the death of Aisling Burnand
22 September 2022 ABPI response to the Government's Plan for Patients
23 September 2022 ABPI response to the mini-Budget
30 September 2022 New survey shows collaboration between pharmaceutical industry and UK academia is growing
12 October 2022 ABPI response to NHS England Genomics Strategy
20 October 2022 NHS patients losing access to innovative treatments as UK industry clinical trials face collapse
26 October 2022 ABPI response to MHRA future Medical Device Regulation implementation extension
03 November 2022 Patients missing out on world leading UK genomic capabilities
10 November 2022 Global action needed to secure the era of green pharmaceuticals - new report
11 November 2022 Medical research call to the Chancellor
17 November 2022 ABPI response to the Autumn Statement
17 November 2022 Speech: ABPI Vice President Susan Rienow addresses Pharma Integrates conference
17 November 2022 Developing new antibiotics key for the race against resistant infections, says ABPI
25 November 2022 By coming together, we can overcome antimicrobial resistance
28 November 2022 ABPI response to Board of Trade report on Life Sciences
01 December 2022 ABPI responds to Bioscience and health technology sector statistics 2021
05 December 2022 ABPI science resources for schools gets Green Tick of approval
08 December 2022 Inspiring the next generation of STEM workers
14 December 2022 ABPI response to launch of International Science Partnerships Fund
15 December 2022 ABPI response to Government's future strategy for batch testing of medicinal products in Great Britain
15 December 2022 UK medicines revenue clawback rockets to 26.5% putting Life Sciences Vision at risk, says ABPI
16 December 2022 ABPI response to Understanding Patient Data securing future funding
22 December 2022 10-year Moderna deal underlines UK potential for global life science leadership

2021

09 January 2021 ABPI welcomes UK Rare Diseases Framework
11 January 2021 ABPI response to UK COVID-19 vaccines delivery plan
12 January 2021 ABPI response to Cumberlege Review statement
18 January 2021 Employment, export, and productivity growth continues for Scotland £1.8 billion pharmaceutical sector
29 January 2021 ABPI response to EU transparency mechanism for COVID-19 vaccines exports
04 February 2021 ABPI response to NICE process review
04 February 2021 Joint ABPI-BIA statement on the Northern Ireland Protocol
05 February 2021 ABPI welcomes AAC annual report and new Chief Executive
09 February 2021 Hundreds of science apprenticeship places lost to red tape every year
15 February 2021 Eight industry leaders unite behind call on Chancellor to reform outdated R&D rules to release £4bn of growth every year
15 February 2021 ABPI response to Life Science Competitiveness Indicators
19 February 2021 ABPI response to EU data adequacy decision
23 February 2021 ABPI response to NHS Commercial Framework
01 March 2021 ABPI response to first innovation passport award
03 March 2021 Pharmaceutical industry response to Budget 2021
08 March 2021 ABPI response to New Treatment Fund extension
11 March 2021 ABPI statement on intellectual property protection and COVID-19
16 March 2021 ABPI response to new batch testing guidance
23 March 2021 ABPI response to clinical research vision
25 March 2021 Collaboration across UK cancer community vital to restoring and improving NHS cancer services
19 April 2021 ABPI response to NICE 5 year strategy
20 April 2021 ABPI response to new global partnership to fight future pandemics
29 April 2021 ABPI response to new genomics funding
30 April 2021 UK set to join the Ottawa Group Initiative
04 May 2021 Ben Osborn named as new President of the ABPI
06 May 2021 ABPI statement on intellectual property rights for COVID vaccines
11 May 2021 ABPI response to Queen's Speech
13 May 2021 Heather Simmonds to stand down as PMCPA Director
19 May 2021 Five steps to urgently advance COVID-19 vaccine equity
28 May 2021 Global pharmaceutical industry response to G7 Trade Ministerial meeting communiqué
28 May 2021 ABPI response to Johnson & Johnson COVID vaccine approval
04 June 2021 ABPI response to new global pandemic preparedness partnership
07 June 2021 Global pharmaceutical industry response to G7 communiqués on AMR
11 June 2021 Mike Thompson awarded MBE
11 June 2021 ABPI response to 100m vaccine pledge
16 June 2021 Speech: The future of medicines manufacturing
17 June 2021 ABPI response to final EU data adequacy decision
21 June 2021 New Patient Advisory Council to embed patient culture into industry’s strategy
22 June 2021 ABPI response to UK data strategy
23 June 2021 ABPI response to government clinical research plan
28 June 2021 2021 pharmaceutical industry Code of Practice launched
30 June 2021 Increased percentage of healthcare professionals agreeing to be named on Disclosure UK in 2020
05 July 2021 ABPI response to MHRA Delivery Plan
06 July 2021 Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response
07 July 2021 ABPI response to life sciences vision
15 July 2021 ABPI response to animal RD statistics
21 July 2021 ABPI statement on the Northern Ireland Protocol
22 July 2021 ABPI statement on Government's Cumberlege Review response
22 July 2021 ABPI response to Innovation Strategy
22 July 2021 ABPI response to Innovative Medicines Fund
28 July 2021 New research reveals attitudes to pharmaceutical industry
30 July 2021 ABPI response to the publication of government’s Life Sciences Competitiveness Indicators report
02 August 2021 ABPI response to NICE fast track appraisal process
19 August 2021 ABPI response to latest NICE Methods Review
07 September 2021 Patient leaders join new pharmaceutical industry advisory council
07 September 2021 ABPI response to NI Protocol update
09 September 2021 ABPI response to Gill Leng retirement
15 September 2021 ABPI backs call for cross-government strategy on health inequalities
22 September 2021 ABPI response to national overprescribing review
29 September 2021 Use lessons from COVID-19 to revitalise post-pandemic clinical research environment, says ABPI
20 October 2021 UK manufacturing holds key to unlocking Government’s domestic and global ambitions
20 October 2021 ABPI response to COVID antivirals announcement
27 October 2021 Pharmaceutical industry response to 2021 Spending Review
09 November 2021 Pharmaceutical industry sets out its vision for the future UK medicines regulation
25 November 2021 Science is thriving in UK regions: Government must back them
03 December 2021 Global pharmaceutical industry leaders meet with UK Prime Minister to discuss leadership in global health and innovation
03 December 2021 Biopharmaceutical industry collaborates on the implementation of the G7 100 Days Mission to improve readiness for future pandemics
10 December 2021 New roadmap to help speed up patient access to ATMP products
17 December 2021 ABPI welcomes Dr Samantha Roberts as NICE Chief Executive
17 December 2021 Industry response to NI Protocol proposals

2020

14 January 2020 Novartis announces new collaboration for patients
21 January 2020 Pharmaceutical companies give NHS Scotland £1 million a week to help fund new treatments
22 January 2020 Government launches Statutory Scheme consultation
28 January 2020 Immigration reforms must support UK life sciences
03 February 2020 ABPI response to proposed UK-EU trade negotiation approaches
05 February 2020 New toolkit for Welsh NHS and industry to work together for patients
06 February 2020 ABPI response to proposed UK-‘Rest of the World’ FTA negotiation approaches
19 February 2020 ABPI response to new UK immigration system
27 February 2020 ABPI response to the UK’s approach to EU negotiations
02 March 2020 ABPI response to UK negotiating objectives for US FTA
11 March 2020 Pharmaceutical industry response to Budget 2020
16 March 2020 ABPI update on the pharmaceutical industry and coronavirus
01 April 2020 Joint statement on COVID-19 testing and diagnostics
08 April 2020 ABPI responds to Government coronavirus testing ‘call to arms’
23 April 2020 Global manufacturing ‘fundamental’ for continued NHS medicine supply
12 May 2020 ABPI response to Safer Working Guidance
21 May 2020 ABPI comment on NIHR framework for restarting paused research
22 May 2020 ABPI response to quarantine measures
28 May 2020 Temporary changes to publication of 2019 data on Disclosure UK in June 2020
04 June 2020 Public-private alliance to provide immunisation programs for 300 million children globally
18 June 2020 ABPI response to antibiotic development scheme
19 June 2020 ABPI consults on new-look Code of Practice
30 June 2020 Pharmaceutical industry invests £381 million in UK R&D collaborations - 2019 data on Disclosure UK
01 July 2020 ABPI response to Government R&D Roadmap
06 July 2020 Supercharging R&D investment critical to boosting British business
08 July 2020 Pharmaceutical industry response to Chancellor’s economic statement
08 July 2020 ABPI response to Cumberlege Review
09 July 2020 $1 billion antibiotics research fund launched by pharmaceutical companies
14 July 2020 William Harbage QC to step down as Chair of the PMCPA Appeal Board
20 July 2020 ABPI reaction to positive results for the Oxford vaccine
29 July 2020 ABPI response to Committee inquiry into COVID-19 and international trade
04 August 2020 ABPI response to DHSC letter to medicine suppliers
07 August 2020 Northern Ireland Protocol: Our response to additional guidance
18 August 2020 ABPI response to new National Institute for Health Protection
01 September 2020 ABPI supports AMRC call to protect charity research
01 September 2020 ABPI response to MHRA guidance for the end of the transition period
11 September 2020 Pharmaceutical industry reaction to UK-Japan trade agreement
28 September 2020 ABPI response to UK genomics strategy
28 September 2020 COVID threat must inject urgency into trade talks, say UK & EU pharma bodies
29 September 2020 ABPI response to NHS Confederation reports: NHS Reset and Health inequalities
30 September 2020 Last-ditch attempt to secure ‘bare minimum’ deal on medicines, MPs told
07 October 2020 UK leading Europe in clinical trials, but strategy needed to restart non-COVID research
08 October 2020 New partnership to reduce disease burden in Northern Ireland - starting with Hepatitis C
13 October 2020 ABPI response to Government-secured Brexit freight capacity
14 October 2020 ABPI response to UK joining Project Orbis and Access Consortium
16 October 2020 ABPI response to PM's Brexit comments
16 October 2020 ABPI response to human medicines regulations changes
20 October 2020 Northern Ireland life sciences sector ‘flourishing’
06 November 2020 Joint EU-UK pharmaceutical industry response to Specialised Committee outcome
06 November 2020 ABPI response to consultation on NICE's methods
25 November 2020 ABPI response to the Spending Review
27 November 2020 Disclosure UK: Further detail for 2019 published
30 November 2020 ABPI response to £20 million medicines manufacturing fund
02 December 2020 ABPI response to first COVID-19 vaccine approval
11 December 2020 ABPI Board announces Kate Brunner QC appointed as new Chair of the PMCPA Appeal Board
21 December 2020 ABPI response to COVID-19 border closures
24 December 2020 Joint EU-UK pharmaceutical industry response to Brexit deal
30 December 2020 ABPI response to Oxford/AstraZeneca vaccine approval

Last reviewed date: 22 December 2025

Next review date: 22 December 2026